presented a strategy that exploits the primary tumor as antigens to initiate personalized antitumor immunity.[174] They designed a diselenide‐bridged hollow mesoporous organosilica nanoparticle to immobilize protein annexin A5 (ANX5). Here, ANXA5 is linked to neoplasm.